|
1
|
Schiffer CA, Hehlmann R and Larson R:
Perspectives on the treatment of chronic phase and advanced phase
CML and Philadelphia chromosome positive ALL(1). Leukemia.
17:691–699. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Voss J, Posern G, Hannemann JR, Wiedemann
LM, Turhan AG, Poirel H, Bernard OA, Adermann K, Kardinal C and
Feller SM: The leukaemic oncoproteins Bcr-Abl and Tel-Abl
(ETV6/Abl) have altered substrate preferences and activate similar
intracellular signalling pathways. Oncogene. 19:1684–1690. 2000.
View Article : Google Scholar
|
|
3
|
Danial NN and Rothman P: JAK-STAT
signaling activated by Abl oncogenes. Oncogene. 19:2523–2531. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kirchner D, Duyster J, Ottmann O, Schmid
RM, Bergmann L and Munzert G: Mechanisms of Bcr-Abl-mediated
NF-kappaB/Rel activation. Exp Hematol. 31:504–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bedi A, Barber JP, Bedi GC, el-Deiry WS,
Sidransky D, Vala MS, Akhtar AJ, Hilton J and Jones RJ:
BCR-ABL-mediated inhibition of apoptosis with delay of G2/M
transition after DNA damage: a mechanism of resistance to multiple
anticancer agents. Blood. 86:1148–1158. 1995.PubMed/NCBI
|
|
6
|
Bueno-da-Silva AE, Brumatti G, Russo FO,
Green DR and Amarante-Mendes GP: Bcr-Abl-mediated resistance to
apoptosis is independent of constant tyrosine-kinase activity. Cell
Death Differ. 10:592–598. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Amarante-Mendes GP, McGahon AJ, Nishioka
WK, Afar DE, Witte ON and Green DR: Bcl-2-independent
Bcr-Abl-mediated resistance to apoptosis: protection is correlated
with up regulation of Bcl-xL. Oncogene. 16:1383–1390. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cavo M: Proteasome inhibitor bortezomib
for the treatment of multiple myeloma. Leukemia. 20:1341–1352.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Caravita T, de Fabritiis P, Palumbo A,
Amadori S and Boccadoro M: Bortezomib: efficacy comparisons in
solid tumors and hematologic malignancies. Nat Clinl Pract Oncol.
3:374–387. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dai Y, Rahmani M, Pei XY, Dent P and Grant
S: Bortezomib and flavopiridol interact synergistically to induce
apoptosis in chronic myeloid leukemia cells resistant to imatinib
mesylate through both Bcr/Abl-dependent and -independent
mechanisms. Blood. 104:509–518. 2004. View Article : Google Scholar
|
|
11
|
Yu C, Rahmani M, Conrad D, Subler M, Dent
P and Grant S: The proteasome inhibitor bortezomib interacts
synergistically with histone deacetylase inhibitors to induce
apoptosis in Bcr/Abl+ cells sensitive and resistant to
STI571. Blood. 102:3765–3774. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM,
Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW,
Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z and Wang ZY: Use
of arsenic trioxide (As2O3) in the treatment
of acute promyelocytic leukemia (APL): II. Clinical efficacy and
pharmacokinetics in relapsed patients. Blood. 89:3354–3360.
1997.PubMed/NCBI
|
|
13
|
Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ,
Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang
P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY and Chen Z: In vitro
studies on cellular and molecular mechanisms of arsenic trioxide
(As2O3) in the treatment of acute
promyelocytic leukemia: As2O3 induces NB4
cell apoptosis with downregulation of Bcl-2 expression and
modulation of PML-RAR alpha/PML proteins. Blood. 88:1052–1061.
1996.PubMed/NCBI
|
|
14
|
Mathews V, George B, Lakshmi KM,
Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM,
Srivastava A and Chandy M: Single-agent arsenic trioxide in the
treatment of newly diagnosed acute promyelocytic leukemia: durable
remissions with minimal toxicity. Blood. 107:2627–2632. 2006.
View Article : Google Scholar
|
|
15
|
Perkins C, Kim CN, Fang G and Bhalla KN:
Arsenic induces apoptosis of multidrug-resistant human myeloid
leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2,
or Bcl-x(L). Blood. 95:1014–1022. 2000.
|
|
16
|
Porosnicu M, Nimmanapalli R, Nguyen D,
Worthington E, Perkins C and Bhalla KN: Co-treatment with
As2O3 enhances selective cytotoxic effects of
STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia.
15:772–778. 2001.PubMed/NCBI
|
|
17
|
Potin S, Bertoglio J and Bréard J:
Involvement of a Rho-ROCK-JNK pathway in arsenic trioxide-induced
apoptosis in chronic myelogenous leukemia cells. FEBS Lett.
581:118–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yan H, Wang YC, Li D, Wang Y, Liu W, Wu YL
and Chen GQ: Arsenic trioxide and proteasome inhibitor bortezomib
synergistically induce apoptosis in leukemic cells: the role of
protein kinase Cdelta. Leukemia. 21:1488–1495. 2007. View Article : Google Scholar
|
|
19
|
Circu ML and Aw TY: Reactive oxygen
species, cellular redox systems, and apoptosis. Free Radic Biol
Med. 48:749–762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chou WC, Jie C, Kenedy AA, Jones RJ, Trush
MA and Dang CV: Role of NADPH oxidase in arsenic-induced reactive
oxygen species formation and cytotoxicity in myeloid leukemia
cells. Proc Natl Acad Sci USA. 101:4578–4583. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stepnik M, Ferlińska M, Smok-Pieniążek A,
Gradecka-Meesters D, Arkusz J and Stańczyk M: Assessment of the
involvement of oxidative stress and Mitogen-Activated Protein
Kinase signaling pathways in the cytotoxic effects of arsenic
trioxide and its combination with sulindac or its metabolites:
sulindac sulfide and sulindac sulfone on human leukemic cell lines.
Med Oncol. 29:1161–1172. 2012.
|
|
22
|
Gorre ME, Mohammed M, Ellwood K, Hsu N,
Paquette R, Rao PN and Sawyers CL: Clinical resistance to STI-571
cancer therapy caused by BCR-ABL gene mutation or amplification.
Science. 293:876–880. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Radujkovic A, Schad M, Topaly J, Veldwijk
MR, Laufs S, Schultheis BS, Jauch A, Melo JV, Fruehauf S and Zeller
WJ: Synergistic activity of imatinib and 17-AAG in
imatinib-resistant CML cells overexpressing BCR-ABL - Inhibition of
P-glycoprotein function by 17-AAG. Leukemia. 19:1198–1206. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li QF, Yan J, Zhang K, Yang YF, Xiao FJ,
Wu CT, Wang H and Wang LS: Bortezomib and sphingosine kinase
inhibitor interact synergistically to induces apoptosis in
BCR/ABl+ cells sensitive and resistant to STI571 through
down-regulation Mcl-1. Biochem Biophys Res Commun. 405:31–36. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wen J, Feng Y, Huang W, Chen H, Liao B,
Rice L, Preti HA, Kamble RT, Zu Y, Ballon DJ and Chang CC: Enhanced
antimyeloma cytotoxicity by the combination of arsenic trioxide and
bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res.
34:85–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Canestraro M, Galimberti S, Savli H,
Palumbo GA, Tibullo D, Nagy B, Guerrini F, Piaggi S, Cine N,
Metelli MR and Petrini M: Synergistic antiproliferative effect of
arsenic trioxide combined with bortezomib in HL60 cell line and
primary blasts from patients affected by myeloproliferative
disorders. Cancer Gene Cytogenet. 199:110–120. 2010. View Article : Google Scholar
|
|
27
|
He Y, Yang JM, Wang JM, Zhou H, Lü SQ and
Hu XX: Synergistic effects of arsenic trioxide and proteasome
inhibitor bortezomib on apoptosis induction in Raji cell line.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 16:794–798. 2008.(In
Chinese).
|
|
28
|
Ruemmele FM, Dionne S, Qureshi I, Sarma
DS, Levy E and Seidman EG: Butyrate mediates Caco-2 cell apoptosis
via up-regulation of pro-apoptotic BAK and inducing caspase-3
mediated cleavage of poly-(ADP-ribose) polymerase (PARP). Cell
Death Differ. 6:729–735. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fernandez-Luna JL: Bcr-Abl and inhibition
of apoptosis in chronic myelogenous leukemia cells. Apoptosis.
5:315–318. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bianchini M, De Brasi C, Gargallo P,
Gonzalez M, Bengió R and Larripa I: Specific assessment of BCR-ABL
transcript overexpression and imatinib resistance in chronic
myeloid leukemia patients. Eur J Haematol. 82:292–300. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wei W, Huang H, Zhao S, Liu W, Liu CX,
Chen L, Li JM, Wu YL and Yan H: Alantolactone induces apoptosis in
chronic myelogenous leukemia sensitive or resistant to imatinib
through NF-κB inhibition and Bcr/Abl protein deletion. Apoptosis.
18:1060–1070. 2013.
|
|
32
|
Sattler M, Verma S, Shrikhande G, Byrne
CH, Pride YB, Winkler T, Greenfield EA, Salgia R and Griffin JD:
The BCR/ABL tyrosine kinase induces production of reactive oxygen
species in hematopoietic cells. J Biol Chem. 275:24273–24278. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stein SJ and Baldwin AS: NF-κB suppresses
ROS levels in BCR-ABL(+) cells to prevent activation of JNK and
cell death. Oncogene. 30:4557–4566. 2011.
|
|
34
|
Naughton R, Quiney C, Turner SD and Cotter
TG: Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway.
Leukemia. 23:1432–1440. 2009. View Article : Google Scholar : PubMed/NCBI
|
